Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

NCT03601078

Multiple Myeloma

ACTIVE_NOT_RECRUITING PHASE2

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma

NCT00999830

Multiple Myeloma

COMPLETED PHASE2

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

NCT00113204

Multiple Myeloma

COMPLETED PHASE1

Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line

NCT01430546

Multiple Myeloma

COMPLETED

Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02077959

Multiple Myeloma

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Multiple Myeloma Experiencing a First or Second Relapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IPH2101 and lenalinomide

Group Type EXPERIMENTAL

IPH2101 combined to lenalidomide

Intervention Type DRUG

Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)

Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IPH2101 combined to lenalidomide

Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)

Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent obtained before any trial-related activities
2. Progressive disease or relapse of multiple myeloma (according to the IMWG definition) after one or two prior therapeutic treatments or regimens for multiple myeloma that achieved a response duration of at least 6 months
3. Prior therapeutic treatment regimens may have included Thalidomide and Lenalidomide. Regarding patients previously treated by Lenalidomide, only patients who achieved at least Partial Response duration of at least 6 months can be included. The patient must not have discontinued treatment due to Lenalidomide intolerance.
4. Measurable disease, as indicated by one or more of the following:

* Serum M-protein ≥ 0.5 g/dL If Serum Protein Electrophoresis is felt to be unreliable for routine M-protein measurement (particularly for patients with IgA MM), then quantitative immunoglobulin levels can be accepted).
* Urine Bence-Jones protein ≥ 200 mg/24 h
* Involved serum Free Light Chains (sFLC) level ≥ 10 mg/dl ( ≥ 100 mg/l) provided sFLC ratio is abnormal (\<0.26 or \>1.65)
5. ECOG performance status of 0, 1 or 2
6. Clinical laboratory values at screening

* Calculated creatinine clearance (according to MDRD) \> 60 ml/min
* Platelet ≥ 75 x 109 /l for patients with \< 50% BM plasma cells, and ≥ 30 x 109 /l for patients with \> 50% BM plasma cells
* ANC \> 1 x 109 /l
* Bilirubin levels \< 1.5 ULN ; ALT and AST \< 3 ULN (grade 1 NCI)
7. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing Lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking Lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy
8. All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.

Exclusion Criteria

1. Age \< 18 years or \> 80 years
2. Non secreting multiple myeloma or non measurable disease (\< 0.5 g /dL M-Protein in serum or \< 200 mg urinary M-protein / 24 h or \<10 mg/dl involved sFLC)
3. Life-threatening conditions related or not to MM relapse
4. Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking Lenalidomide)
5. Known hypersensitivity to thalidomide or IMiD®.
6. Use of any investigational agent within the last month
7. Treatment by systemic corticosteroids (except inhaled corticosteroids) or chemotherapy (including consolidation and maintenance) within the last month (use of biphosphonates is permitted)
8. Radiotherapy within the last month
9. Primary or associated amyloidosis
10. Peripheral neuropathy of grade ≥ 3 according to the CTCAE of the NCI
11. Abnormal cardiac status with any of the following

* NYHA stage III or IV congestive heart failure
* myocardial infarction within the previous 6 months
* cardiac arrhythmia remaining symptomatic despite treatment
12. Current active infectious disease or positive serology for HIV, HCV or positive Hbs Antigen
13. History of or current auto-immune disease
14. History of other active malignancy within the past 5 years (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma)
15. Serious concurrent uncontrolled medical disorder
16. History of allograft or solid organ transplantation
17. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
18. Inability to comply with an antithrombotic regimen

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No